ArticleAmerican journal of translational research2024
Effects of Astragalus polysaccharide on the structure and function of skeletal muscle in D-galactose-induced C57BL/6J mice.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effects of Astragalus polysaccharide (APS) on skeletal muscle structure and function in D-galactose (D-gal)-induced C57BL/6J mice.
methodsEighteen male C57BL/6J mice of specific pathogen-free (SPF) grade, aged 8 weeks, were selected and divided into three groups: a control group (0.9% saline gavage for 16 weeks), a D-gal group (subcutaneous injection of 200 mg/kg D-galactose in the upper neck region, once daily for 8 weeks), and a D-gal + APS group (subcutaneous injection of 200 mg/kg D-galactose, once daily for 8 weeks, with concurrent administration of 100 mg/kg APS by gavage for 8 weeks). Body composition of the mice was assessed using the ImpediVET Laboratory Composition Measurement Analyzer. The pathological structure of the skeletal muscles was examined using hematoxylin and eosin (HE) staining, and the microstructure and mitochondrial alterations in skeletal muscle were observed under transmission electron microscopy. Protein expression levels of LC3II and PINK1 in skeletal muscle tissues were analyzed using Western blotting analysis.
resultsCompared to the control group, the D-gal-treated mice demonstrated substantial declines in grip strength, the cross-sectional area (CSA) of gastrocnemius muscle fibers, gastrocnemius weight, and the gastrocnemius weight-to-body weight ratio. APS administration markedly improved these parameters in the D-gal-treated mice. H&E staining showed muscle atrophy and senescence in the D-gal-treated mice, accompanied by deformed muscle cell morphology, which was mitigated by APS gavage. The D-gal-treated mice displayed swelling, cristae fracture, lysis, or complete loss, alongside reduced autophagy and increased lengths of bright bands, myofibrillar myonules, and H bands. However, administration of APS alleviated mitochondrial damage, promoted mitophagy, and reduced the lengths of these muscle tissue bands. Additionally, D-gal treatment significantly reduced LC3II and PINK1 protein expression in muscle tissues, while APS treatment notably elevated their expression levels.
conclusionAPS gavage ameliorates the structural and functional impairments in muscle tissues of the D-gal-treated mice by promoting mitochondrial autophagy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.